The Full Wiki

More info on Pegloticase

Pegloticase: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 885051-90-1
ATC code none
PubChem  ?
Chemical data
Formula  ?
Mol. mass 497 kDa (polymer-modified tetramer)
Pharmacokinetic data
Bioavailability N/A
Metabolism  ?
Half life 10–12 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes intravenous

Pegloticase (trade name Krystexxa, formerly Puricase)[1] is an experimental drug for the treatment of severe, treatment-refractory gout, developed by Savient Pharmaceuticals.[2][3] As of March 2009, it is undergoing Phase III clinical trials.

Mechanism of action

Pegloticase is a recombinant porcine uricase similar to rasburicase. Both are enzymes which metabolise uric acid to allantoin. This reduces the risk of precipitates, since allantoin is five to ten times more soluble than uric acid.

In contrast to rasburicase, pegloticase is pegylated to increase its elimination half life from about eight hours to ten or twelve days. This modification allows for an application just once every two to four weeks, making this drug suitable for long-term treatment.[4]




Got something to say? Make a comment.
Your name
Your email address